



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
PARKAR, et al.

Examiner: **LANDSMAN, Robert S.**

Art Unit: **1647**

Application No.: **10/747,994**

Filed: **December 30, 2003**

Title: **NUCLEIC ACID ENCODING A
NOVEL PROSTAGLANDIN
RECEPTOR PROTEIN AND
METHODS OF USE THEREOF**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450, on

Date of Deposit

Signature

Sept 6, 2006


Debra Cooper

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. §1.821(c) and the computer readable copies required by 37 C.F.R. §1.821(e) submitted herewith are the same.

Respectfully submitted,


Ann Marie Szczepanik, Reg. No. 52,267
Attorney/Agent for Applicant

sanofi-aventis U.S. LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4757
Telefax (908) 231-2626

Docket No. USAV2003/0073 US NP